Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) announced the publication of an independent health service study of its UroShield® device in The Australian and New Zealand Continence Journal. The study demonstrated significant improvements in patient care and cost reduction for those with indwelling urinary catheters.

Key findings include:

• 86% reduction in UTI incidence
• 70% reduction in catheter blockages
• 82.8% decrease in bladder irrigations
• 52.3% reduction in catheter changes
• 63.5% reduction in resource costs over 5 months

The study, conducted by a New Zealand District Nursing Service, highlighted UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and improving patient comfort while reducing healthcare provider costs through decreased nursing time and fewer interventions.

Positive

• Significant clinical effectiveness proven through independent study
• 86% reduction in UTI incidence demonstrates strong product performance
• 63.5% reduction in healthcare resource costs over 5 months
• Multiple efficiency metrics showing 52-83% improvements in various aspects

Negative

• None.

Insights

Financial Analyst

The publication of an independent study validating NanoVibronix's UroShield device in a peer-reviewed journal represents a significant positive development for this microcap company ($2.3M market cap). The study demonstrates compelling clinical and economic value, with an 86% reduction in UTIs, 70% reduction in catheter blockages, and a substantial 63.5% reduction in healthcare resource costs.

For medical device companies, third-party validation is important for commercial adoption. The catheter-associated UTI prevention market represents a substantial opportunity, as CAUTIs are among the most common and costly hospital-acquired infections, affecting hundreds of thousands of patients annually.

This validation strengthens NanoVibronix's position with potential customers by providing documented evidence of both clinical efficacy and cost savings - the two primary factors driving healthcare purchasing decisions. For a company of this size, even modest market penetration resulting from this validation could translate to meaningful revenue growth relative to its current scale.

The recommendation for UroShield adoption included in the journal article could accelerate sales cycles and improve reimbursement prospects. However, investors should recognize that medical device commercialization typically requires sustained investment in sales infrastructure to convert clinical validation into revenue growth.

Healthcare Technology Expert

The clinical outcomes reported in this independent study are remarkably strong in addressing a persistent healthcare challenge. The UroShield's non-invasive ultrasonic approach demonstrates superior performance compared to existing CAUTI prevention methods, with the 86% reduction in UTI incidence representing best-in-class results.

What's particularly compelling is the 63.5% resource cost reduction, providing the economic justification healthcare administrators require for technology adoption. The documented reductions in nursing time, bladder irrigations (82.8% less), and catheter changes (52.3% less) address both clinical and operational pain points for healthcare facilities.

The technology's application extends beyond hospitals to long-term care and home healthcare settings where long-term catheter use is common. For healthcare providers struggling with CAUTI-related quality measures and potential reimbursement penalties, solutions with this level of demonstrated effectiveness warrant serious consideration.

The validation in The Australian and New Zealand Continence Journal significantly strengthens the evidence base supporting adoption. The study's design as a quality improvement project within a real-world nursing service (rather than a controlled laboratory environment) makes the results particularly credible and applicable to everyday clinical practice.

UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs

ELMSFORD, N.Y.--(BUSINESS WIRE)-- NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal.

The study highlights UroShield’s effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.

Brian Murphy, CEO of NanoVibronix, Inc., commented, “This study underscores the benefits of UroShield in enhancing patient care by reducing CAUTI incidence and catheter blockages, minimizing catheter complications and improving overall comfort. Notably, researchers found that UroShield required less nursing time, which eased workload demands and resulted in measurable cost savings for the healthcare provider."

From the article:

“The introduction of the UroShield® device within a New Zealand District Nursing Service significantly improved the lives of patients with indwelling urinary catheters. This Quality Improvement project demonstrated a reduction in catheter-associated urinary tract infections and blockages, leading to fewer interventions and enhanced patient comfort. The project highlighted how UroShield® can reduce healthcare costs and improve the quality of life for patients, suggesting its potential for use in similar healthcare settings.”

“The final cost analysis has shown a significant reduction in resource expenditure due to a combination of less interventions, and less urgent call outs. The UroShield® proved to have a 63.5% reduction in resource cost over the 5 months of the project.”

The complete article is available at https://www.publish.csiro.au/CJ/pdf/CJ24043.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the continuous assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home or in any care setting. Additional information about NanoVibronix is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements include, but are not limited to: future expectations, plans and prospects for the Company following the consummation of the acquisition and stockholder approval of the conversion of the Series X Preferred Stock. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250314149883/en/

Brett Maas, Managing Principal, Hayden IR, LLC

brett@haydenir.com

(646) 536-7331

Source: NanoVibronix, Inc.

FAQ

What were the key effectiveness rates of UroShield according to the new study?

The study showed 86% reduction in UTIs, 70% reduction in catheter blockages, 82.8% less bladder irrigations, and 52.3% less catheter changes.

How much cost reduction did UroShield achieve in the healthcare study?

The study demonstrated a 63.5% reduction in resource costs over the 5-month project period.

Where was the NanoVibronix UroShield study published?

The study was published in The Australian and New Zealand Continence Journal.

What are the main benefits of UroShield for healthcare providers?

UroShield reduces nursing time, decreases workload demands, minimizes catheter-related interventions, and provides measurable cost savings.